The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Zoster-049 Study Group , Céline Boutry, Andrew Hastie, Javier Diez-Domingo, Juan Carlos Tinoco, Chong Jen Yu, Charles Andrews, Jean Beytout, Covadonga Caso, Huey Shinn Cheng, Hee Jin Cheong, Eun Ju Choo, Dan Curiac, Emmanuel Di Paolo, Marc Dionne, Tamara Eckermann, Meral Esen, Murdo Ferguson, Wayne Ghesquiere, Shinn Jang HwangThiago Junqueira Avelino-Silva, Pavel Kosina, Chiu Shong Liu, Jukka Markkula, Beate Moeckesch, Cláudia Murta de Oliveira, Dae Won Park, Karlis Pauksens, Paola Pirrotta, Georg Plassmann, Carol Pretswell, Lars Rombo, Bruno Salaun, Johan Sanmartin Berglund, Isabelle Schenkenberger, Tino Schwarz, Meng Shi, Benita Ukkonen, Toufik Zahaf, Cristiano Zerbini, Anne Schuind, Anthony L. Cunningham
Research output: Contribution to journal › Article › Scientific › peer-review
56Citations
(Scopus)
8Downloads
(Pure)
Fingerprint
Dive into the research topics of 'The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70'. Together they form a unique fingerprint.